Marsh McLennan Agency completes acquisition of TriBridge Partners
Get Alerts MRSH Hot Sheet
Join SI Premium – FREE
WHITE PLAINS--(BUSINESS WIRE)-- Marsh McLennan Agency (MMA), a business of Marsh (NYSE: MRSH) and a leading provider of business insurance, employee health and benefits, retirement and wealth, and private client insurance solutions across the US and Canada, today announced the completion of its previously announced agreement to acquire TriBridge Partners, a leading independent benefits broker and retirement and wealth advisor headquartered in Columbia, Maryland. Terms of the acquisition were not disclosed.
With the closing of the acquisition, MMA’s Mid-Atlantic team has gained a unique blend of group health, wealth, and personal lines insurance expertise to add to its strong property/casualty practice, which will be an asset for our clients in the DC and Baltimore area. TriBridge Partners employees will join MMA and continue to operate out of their existing Columbia office location.
TriBridge Partners was founded in 2013 upon the strategic merger between three well-established regional brokerage and advisory firms, offering health and employee benefits, retirement plan advisory, wealth management, and individual insurance services to clients across the Mid-Atlantic.
About Marsh McLennan Agency
Marsh McLennan Agency is a business of Marsh (NYSE: MRSH), a global leader in risk, reinsurance and capital, people and investments, and management consulting, advising clients in 130 countries. With annual revenue of $27 billion and more than 95,000 colleagues, Marsh helps build the confidence to thrive through the power of perspective. For more information about Marsh McLennan Agency, visit marshmma.com, or follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260601096026/en/
Media:
Lexie O’Connor
+1 (857) 772 0150
[email protected]
Source: Marsh McLennan Agency
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
- Crypto Market News: Oil’s $117 Close Tests BTC and XRP as Remittix Earn Readies Aave, Fluid and Maple Finance Pools
- Dogecoin Price Prediction: Can DOGE Reclaim $0.10 as Remittix Recruits Earn Testers for 18-22% APY?
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share